The results revealed that shorter relapse-free survival (p < 0.001) and overall survival (p < 0.001) were significantly associated with breast cancer patients with higher RABIF expression than those with lower RABIF expression (Figure 5A). This evidence concerns the gene RABIF and breast carcinoma.